Genmab (Otc) (GMAB) has released an update.
Genmab A/S, a leading biotechnology firm, has been actively purchasing its own shares, with a total value of 154,247,879.42 DKK bought back between April 8 and April 12, 2024, as part of a larger share buy-back program set to conclude by December 16, 2024. The company’s latest transactions are part of a DKK 3.5 billion buy-back initiative, aiming to reduce the number of outstanding shares and potentially increase shareholder value. Genmab’s commitment to innovation and strategic partnerships continues to foster its goal of developing life-transforming antibody therapeutics for cancer and other serious diseases.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
